India, Aug. 20 -- BioStem Technologies, Inc. (BSEM), a regenerative medicine company focused on perinatal tissue allograft products, reported financial results for the second quarter ended June 30, 2026, highlighting 29% sequential revenue growth, raised full-year guidance and its recent uplisting to the Nasdaq Capital Market.
Q2 FY26 Highlights
For the second quarter, BioStem reported net revenue of $7.9 million, up 29% sequentially from $6.1 million in the first quarter of 2026. Revenue was primarily driven by sales of its Neox and Clarix products.
Hospital revenue increased to $6.7 million from $5.7 million in the first quarter, while physician office revenue rose to $1.1 million from $0.8 million.
Gross profit increased to $4.8 mill...